Compare ENTA & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | BWMX |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 495.6M |
| IPO Year | 2013 | N/A |
| Metric | ENTA | BWMX |
|---|---|---|
| Price | $15.87 | $14.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $20.40 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 370.9K | 24.4K |
| Earning Date | 02-09-2026 | 10-23-2025 |
| Dividend Yield | N/A | ★ 10.53% |
| EPS Growth | N/A | ★ 15.49 |
| EPS | N/A | ★ 1.49 |
| Revenue | $65,324,000.00 | ★ $775,128,445.00 |
| Revenue This Year | $0.99 | $3.50 |
| Revenue Next Year | $0.19 | $5.30 |
| P/E Ratio | ★ N/A | $9.51 |
| Revenue Growth | N/A | ★ 3.60 |
| 52 Week Low | $4.09 | $7.00 |
| 52 Week High | $17.15 | $15.00 |
| Indicator | ENTA | BWMX |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 53.25 |
| Support Level | $14.07 | $13.53 |
| Resistance Level | $17.15 | $14.69 |
| Average True Range (ATR) | 0.95 | 0.34 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 56.71 | 57.04 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.